R&D | May 19, 2026
Teva study exposes major diagnosis gap in Tardive Dyskinesia
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Access to genomic testing, not therapy cost, is the biggest challenge
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
Funding to support clinical development, gene therapy pipeline expansion and GMP manufacturing capabilities
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Company enters women’s personal grooming segment while strengthening pain management portfolio with herbal Ortho Oil
FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
Subscribe To Our Newsletter & Stay Updated
